NCT06961188View on ClinicalTrials.gov

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene NegativityUntreated With Systemic Therapy
Interventions
DRUG

Nano-crystalline Megestrol Acetate Oral Suspension

Nanocrystalline Megestrol Acetate Oral Suspension + Standard Therapy Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 12 weeks (maximum treatment duration: 12 weeks), whichever occurred first.

OTHER

Standard Therapy

Standard Therapy

Trial Locations (1)

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY